Equity Overview
Price & Market Data
Price: $55.41
Daily Change: +$0.71 / 1.28%
Daily Range: $53.00 - $55.95
Market Cap: $370,281,984
Daily Volume: 185,304
Performance Metrics
1 Week: -6.47%
1 Month: -21.28%
3 Months: -31.25%
6 Months: 67.91%
1 Year: 35.25%
YTD: -15.15%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country:
Details
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.